|
1
|
Guerrouahen BS, Futami M, Vaklavas C,
Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson
LJ, Arceci R, et al: Dasatinib inhibits the growth of molecularly
heterogeneous myeloid leukemias. Clin Cancer Res. 16:1149–1158.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robak T and Wierzbowska A: Current and
emerging therapies for acute myeloid leukemia. Clin Ther.
31:2349–2370. 2009. View Article : Google Scholar
|
|
3
|
McCulloch EA: Stem cells in normal and
leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood.
62:1–13. 1983.PubMed/NCBI
|
|
4
|
Petrie K, Zelent A and Waxman S:
Differentiation therapy of acute myeloid leukemia: Past, present
and future. Curr Opin Hematol. 16:84–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sassa T, Tojyo T and Munakata K: Isolation
of a new plant growth substance with cytokinin-like activity.
Nature. 227:3791970. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Asahi K, Honma Y, Hazeki K, Sassa T,
Kubohara Y, Sakurai A and Takahashi N: Cotylenin A, a plant-growth
regulator, induces the differentiation in murine and human myeloid
leukemia cells. Biochem Biophys Res Commun. 238:758–763. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamamoto-Yamaguchi Y, Yamada K, Ishii Y,
Asahi KI, Tomoyasu S and Honma Y: Induction of the monocytic
differentiation of myeloid leukaemia cells by cotylenin A, a plant
growth regulator. Br J Haematol. 112:697–705. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamada K, Honma Y, Asahi KI, Sassa T, Hino
KI and Tomoyasu S: Differentiation of human acute myeloid leukaemia
cells in primary culture in response to cotylenin A, a plant growth
regulator. Br J Haematol. 114:814–821. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Honma Y: Cotylenin A - a plant growth
regulator as a differentiation-inducing agent against myeloid
leukemia. Leuk Lymphoma. 43:1169–1178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Honma Y, Ishii Y, Sassa T and Asahi K:
Treatment of human promyelocytic leukemia in the SCID mouse model
with cotylenin A, an inducer of myelomonocytic differentiation of
leukemia cells. Leuk Res. 27:1019–1025. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yaguchi M, Miyazawa K, Katagiri T,
Nishimaki J, Kizaki M, Tohyama K and Toyama K: Vitamin K2 and its
derivatives induce apoptosis in leukemia cells and enhance the
effect of all-trans retinoic acid. Leukemia. 11:779–787. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yokoyama T, Miyazawa K, Naito M, Toyotake
J, Tauchi T, Itoh M, Yuo A, Hayashi Y, Georgescu MM, Kondo Y, et
al: Vitamin K2 induces autophagy and apoptosis simultaneously in
leukemia cells. Autophagy. 4:629–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kitagawa J, Hara T, Tsurumi H, Ninomiya S,
Ogawa K, Adachi S, Kanemura N, Kasahara S, Shimizu M and Moriwaki
H: Synergistic growth inhibition in HL-60 cells by the combination
of acyclic retinoid and vitamin K2. J Cancer Res Clin Oncol.
137:779–787. 2011. View Article : Google Scholar
|
|
14
|
Mizuta T and Ozaki I: Hepatocellular
carcinoma and vitamin K. Vitam Horm. 78:435–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumoto K, Okano J, Nagahara T and
Murawaki Y: Apoptosis of liver cancer cells by vitamin K2 and
enhancement by MEK inhibition. Int J Oncol. 29:1501–1508.
2006.PubMed/NCBI
|
|
16
|
Showalter SL, Wang Z, Costantino CL,
Witkiewicz AK, Yeo CJ, Brody JR and Carr BI: Naturally occurring K
vitamins inhibit pancreatic cancer cell survival through a
caspase-dependent pathway. J Gastroenterol Hepatol. 25:738–744.
2010. View Article : Google Scholar
|
|
17
|
Sakai I, Hashimoto S, Yoda M, Hida T,
Ohsawa S, Nakajo S and Nakaya K: Novel role of vitamin K2: A potent
inducer of differentiation of various human myeloid leukemia cell
lines. Biochem Biophys Res Commun. 205:1305–1310. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyazawa K, Yaguchi M, Funato K, Gotoh A,
Kawanishi Y, Nishizawa Y, Yuo A and Ohyashiki K:
Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60
cells: Dichotomous nature of vitamin K2 in leukemia cells.
Leukemia. 15:1111–1117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Funato K, Miyazawa K, Yaguchi M, Gotoh A
and Ohyashiki K: Combination of 22-oxa-1,25-dihydroxyvitamin D(3),
a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically
enhances cell differentiation but suppresses VK2-inducing apoptosis
in HL-60 cells. Leukemia. 16:1519–1527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sada E, Abe Y, Ohba R, Tachikawa Y,
Nagasawa E, Shiratsuchi M and Takayanagi R: Vitamin K2 modulates
differentiation and apoptosis of both myeloid and erythroid
lineages. Eur J Haematol. 85:538–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Field JK and Spandidos DA: The role of ras
and myc oncogenes in human solid tumours and their relevance in
diagnosis and prognosis (Review). Anticancer Res. 10:1–22.
1990.PubMed/NCBI
|
|
22
|
Delgado MD, Albajar M, Gomez-Casares MT,
Batlle A and León J: MYC oncogene in myeloid neoplasias. Clin
Transl Oncol. 15:87–94. 2013. View Article : Google Scholar
|
|
23
|
Kumakura S, Ishikura H, Tsumura H, Hayashi
H, Endo J and Tsunematsu T: c-myc protein expression during cell
cycle phases in differentiating HL-60 cells. Leuk Lymphoma.
14:171–180. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kumakura S, Ishikura H, Tsumura H, Iwata
Y, Endo J and Kobayashi S: C-Myc and Bcl-2 protein expression
during the induction of apoptosis and differentiation in TNF
alpha-treated HL-60 cells. Leuk Lymphoma. 23:383–394. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang G, Albihn A, Tang T, Tian Z and
Henriksson M: Role of Myc in differentiation and apoptosis in HL60
cells after exposure to arsenic trioxide or all-trans retinoic
acid. Leuk Res. 32:297–307. 2008. View Article : Google Scholar
|
|
26
|
Cheng YC, Lin H, Huang MJ, Chow JM, Lin S
and Liu HE: Downregulation of c-Myc is critical for valproic
acid-induced growth arrest and myeloid differentiation of acute
myeloid leukemia. Leuk Res. 31:1403–1411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan XN, Chen JJ, Wang LX, Xiao RZ, Liu LL,
Fang ZG, Liu Q, Long ZJ and Lin DJ: Inhibition of c-Myc overcomes
cytotoxic drug resistance in acute myeloid leukemia cells by
promoting differentiation. PLoS One. 9:e1053812014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horne MC, Donaldson KL, Goolsby GL, Tran
D, Mulheisen M, Hell JW and Wahl AF: Cyclin G2 is up-regulated
during growth inhibition and B cell antigen receptor-mediated cell
cycle arrest. J Biol Chem. 272:12650–12661. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kasukabe T, Okabe-Kado J and Honma Y:
Cotylenin A, a new differentiation inducer, and rapamycin
cooperatively inhibit growth of cancer cells through induction of
cyclin G2. Cancer Sci. 99:1693–1698. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zimmermann M, Arachchige-Don AS, Donaldson
MS, Dallapiazza RF, Cowan CE and Horne MC: Elevated cyclin G2
expression intersects with DNA damage checkpoint signaling and is
required for a potent G2/M checkpoint arrest response to
doxorubicin. J Biol Chem. 287:22838–22853. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kasukabe T, Honma Y, Hozumi M and Nomura
H: Inhibition of proliferation and induction of differentiation of
human and mouse myeloid leukemia cells by new ethyleneglycol-type
nonphosphorus alkyl ether lipids. Jpn J Cancer Res. 81:807–812.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marzi I, Cipolleschi MG, D’Amico M,
Stivarou T, Rovida E, Vinci MC, Pandolfi S, Dello Sbarba P, Stecca
B and Olivotto M: The involvement of a Nanog, Klf4 and c-Myc
transcriptional circuitry in the intertwining between neoplastic
progression and reprogramming. Cell Cycle. 12:353–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stossi F, Likhite VS, Katzenellenbogen JA
and Katzenellenbogen BS: Estrogen-occupied estrogen receptor
represses cyclin G2 gene expression and recruits a repressor
complex at the cyclin G2 promoter. J Biol Chem. 281:16272–16278.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang X-H, Li L-L, Wu G-G, Xie Y-C, Zhang
G-X, Chen W, Yang HF, Liu QL, Li WH, He WG, et al: Upregulation of
CPE promotes cell proliferation and tumorigenicity in colorectal
cancer. BMC Cancer. 13:4122013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka H, Abe E, Miyaura C, Kuribayashi T,
Konno K, Nishii Y and Suda T: 1 alpha,25-Dihydroxycholecalciferol
and a human myeloid leukaemia cell line (HL-60). Biochem J.
204:713–719. 1982.PubMed/NCBI
|
|
36
|
Kasukabe T, Honma Y, Hozumi M, Suda T and
Nishii Y: Control of proliferating potential of myeloid leukemia
cells during long-term treatment with vitamin D3 analogues and
other differentiation inducers in combination with antileukemic
drugs: In vitro and in vivo studies. Cancer Res. 47:567–572.
1987.PubMed/NCBI
|
|
37
|
Vermeer C and Schurgers LJ: A
comprehensive review of vitamin K and vitamin K antagonists.
Hematol Oncol Clin North Am. 14:339–353. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sasaki N, Kusano E, Takahashi H, Ando Y,
Yano K, Tsuda E and Asano Y: Vitamin K2 inhibits
glucocorticoid-induced bone loss partly by preventing the reduction
of osteoprotegerin (OPG). J Bone Miner Metab. 23:41–47. 2005.
View Article : Google Scholar
|
|
39
|
Masui K, Tanaka K, Akhavan D, Babic I,
Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, et al: mTOR
complex 2 controls glycolytic metabolism in glioblastoma through
FoxO acetylation and upregulation of c-Myc. Cell Metab. 18:726–739.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sheth A, Escobar-Alvarez S, Gardner J, Ran
L, Heaney ML and Scheinberg DA: Inhibition of human mitochondrial
peptide deformylase causes apoptosis in c-myc-overexpressing
hematopoietic cancers. Cell Death Dis. 5:e11522014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gómez-Casares MT, García-Alegria E,
López-Jorge CE, Ferrándiz N, Blanco R, Alvarez S, Vaqué JP,
Bretones G, Caraballo JM, Sánchez-Bailón P, et al: MYC antagonizes
the differentiation induced by imatinib in chronic myeloid leukemia
cells through downregulation of p27(KIP1). Oncogene. 32:2239–2246.
2013. View Article : Google Scholar
|
|
42
|
Singh AM and Dalton S: The cell cycle and
Myc intersect with mechanisms that regulate pluripotency and
reprogramming. Cell Stem Cell. 5:141–149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hoffman B, Amanullah A, Shafarenko M and
Liebermann DA: The proto-oncogene c-myc in hematopoietic
development and leukemogenesis. Oncogene. 21:3414–3421. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
DeLuca HF: Evolution of our understanding
of vitamin D. Nutr Rev. 66(Suppl 2): S73–S87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kasukabe T, Okabe-Kado J, Kato N, Sassa T
and Honma Y: Effects of combined treatment with rapamycin and
cotylenin A, a novel differentiation-inducing agent, on human
breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res.
7:R1097–R1110. 2005. View Article : Google Scholar
|
